TrueBinding

TrueBinding is a biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for neurodegenerative and metabolic diseases, stroke, oncology, and other areas with unmet medical needs. The company offers contract development and manufacturing services to accelerate biopharmaceutical innovation. TrueBinding’s pipeline of monoclonal antibody therapeutics aims to revolutionize patient care by providing targeted treatments for a diverse range of diseases. The company provides an Expanded Access Program for TB006, targeting Alzheimer’s Disease, for patients who have exhausted all other alternatives. TrueBinding completed a Phase 1b/2a Clinical Trial for Alzheimer’s Disease with TB006, which showed potential in slowing or reducing clinical decline. The corporate headquarters is located at 300 Lincoln Centre Drive, Suite 200, Foster City, CA 94404, and the manufacturing and services facility is located at 25565 Whitesell Street, Hayward, CA 94545.